Physician profile
Jonathan Cooperman
NPI 1568777670
$3,036.68
in general payments reported to CMS, 2019-2025
31 companies · $901 in 2025
The $901 reported for 2025 was more than what 76% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $92.90 · 2020: $16.78 · 2021: $317 · 2022: $580 · 2023: $545 · 2024: $584 · 2025: $901.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,013 · Education: $17.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,012.71 |
| Education | $17.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $725.66 | 2019-2025 | Trelegy Ellipta, Nucala |
| Insmed, INC. | $253.91 | 2019-2025 | Arikayce, Brinsupri |
| Amgen INC. | $198.72 | 2022-2024 | Tezspire |
| Genzyme Corporation | $184.72 | 2021-2025 | |
| Electromed, INC. | $182.87 | 2021-2025 | Smartvest |
| Inari Medical, INC. | $169.95 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $147.65 | 2021-2025 | Tezspire, Fasenra |
| Abiomed | $133.63 | 2024 | Impella |
| Regeneron Healthcare Solutions, INC. | $102.77 | 2019-2023 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $98.92 | 2020-2024 | Glassia |
| Philips North America LLC | $96.68 | 2024-2025 | Image Management Subscription, (Ae4) Secretion Management |
| Boehringer Ingelheim Pharmaceuticals, INC. | $85.18 | 2022-2025 | Jascayd, Ofev |
| Shionogi INC | $81.31 | 2022-2024 | Fetroja |
| Actelion Pharmaceuticals US, INC. | $64.31 | 2021-2025 | Uptravi, Opsumit |
| Merck Sharp & Dohme LLC | $44.12 | 2023-2024 | Zerbaxa, Recarbrio |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $43.99 | 2021-2025 | |
| Baxter Healthcare | $43.23 | 2022-2025 | Hillrom - Vest System Model 105 Home Care |
| Novartis Pharmaceuticals Corporation | $41.77 | 2023 | |
| Jazz Pharmaceuticals INC. | $40.54 | 2021 | |
| Mallinckrodt Hospital Products INC. | $37.50 | 2023 | Terlivaz |
| Harmony Biosciences LLC | $37.30 | 2024 | |
| Janssen Pharmaceuticals, INC | $37.15 | 2021-2022 | |
| Verona Pharma, INC. | $28.18 | 2025 | Ohtuvayre |
| Grifols USA, LLC | $28.09 | 2025 | Prolastin-C Liquid |
| Mylan Specialty L.P. | $27.76 | 2023 | Yupelri |
| Bayer Healthcare Pharmaceuticals INC. | $26.28 | 2022 | |
| Genentech USA, INC. | $20.86 | 2019 | |
| Pulmonx Corporation | $15.43 | 2025 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Chartis Catheter |
| Boston Scientific Corporation | $14.95 | 2019 | |
| Vapotherm INC | $11.65 | 2022 | |
| Ambu INC. | $11.60 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Cooperman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.